Exicure Inc. (XCUR) Names James Sulat to Board
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Exicure Announces Appointment of James Sulat to Board of Directors
January 5, 2021 7:00 AM ESTCHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced the appointment of James Sulat to its Board of Directors.
James Jim Sulat joins Exicure after decades of experience advising and leading biopharmaceutical companies, including serving in the roles of President, Chief Executive Officer and Chief Financial Officer at various companies. Mr. Sulat currently serves on the boards of directors of Valneva SE and Arch Therapeutics and... More
